Objective.—To evaluate the effect of angiotensin-converting enzyme (ACE) inhibitors on
mortality and morbidity in patients with symptomatic congestive heart failure. Data Sources …

Angiotensin converting enzyme (ACE) inhibitors have emerged as a significant advance in
the treatment of heart failure; yet only a minority (ie, 30% to 40%) of eligible patients are …

Background—Angiotensin-converting enzyme (ACE) inhibitors are generally prescribed by
physicians in doses lower than the large doses that have been shown to reduce morbidity …

Background Evidence from clinical trials in the past decade has consistently shown that
angiotensin-converting enzyme (ACE) inhibitors reduce morbidity and mortality in patients …

Background—Although ACE inhibitors are underprescribed for heart failure, factors
associated with their use are not well described. Furthermore, the effectiveness of ACE …

Background Treatment with angiotensin-converting enzyme (ACE) inhibitors reduces
mortality and morbidity in patients with chronic heart failure (CHF), but most affected patients …

Objectives To compare the efficacy and safety of angiotensin-converting enzyme inhibitors
(ACEis) and angiotensin receptor blockers (ARBs) in patients without heart failure. Patients …

The development of angiotensin-converting enzyme inhibitors (ACE inhibitors) has been
one of the most remarkable stories in the treatment of cardiovascular diseases. Angiotensin …

This study was conducted to provide evidence of an association between angiotensin-
converting enzyme (ACE) inhibitor use and clinical outcomes among patients with …

Because they provide relief of symptoms and reduce mortality, angiotensin-converting
enzyme (ACE) inhibitors have become a highly recommended part of the pharmacologic …